Bristol-Myers Squibb Company
Indazole derivatives as alpha v integrin antagonists
Last updated:
Abstract:
The present invention provides compounds of Formula (Ia) or (Ib): ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to .alpha.V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of .alpha.V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
Status:
Grant
Type:
Utility
Filling date:
9 Jul 2020
Issue date:
8 Jun 2021